Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
AssigneeThe Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy
InventorsSeamus J. MARTIN, Conor HENRY, Graeme SULLIVAN
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.
Claims23
1-34. (canceled)
A method for the treatment and/or reduction of inflammatory skin disorders in a subject comprising the step of administering an effective amount of an agent capable of inhibiting IL-36 activation that occurs via proteolytic processing, including IL-36α, IL-36β, or IL-36γ activation, and a combination thereof, to a subject in need thereof
- wherein the agent inhibits IL-36 activation by binding to at least one IL-36 protease cleavage site required for activation of IL-36;
- or
- the agent prevents and/or inhibits the activity of IL-36 activating proteases or activators thereof.
(canceled)
A composition for treatment and/or prevention of an inflammatory skin disorder, the composition comprising an agent capable of inhibiting IL-36 activation via proteolytic processing, and a suitable pharmaceutical excipient.
Dependencies are inferred from the claim text.